NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2024, Vol. 36 ›› Issue (5): 798-804.doi: 10.16333/j.1001-6880.2024.5.009

Previous Articles     Next Articles

Rocaglamide inhibits the proliferation of chronic myelogenous leukemia cells partly via aerobic glycolysis

ZENG Ling-zhi1,3,WANG Chun-lin4,5,LIU Wu-ling4,5,YANG Yi-ying2,3,LI Yan-mei4,5*,SONG Jia-lei2,3*   

  1. 1School of Pharmacy,Guizhou University of Traditional Chinese Medicine;2School of Basic Medicine,Guizhou University of Traditional Chinese Medicine;3The Key Laboratory of Molecular Biology,Guizhou University of Traditional Chinese Medicine,Guiyang 550025,China;4The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Sciences;5State Key Laboratory of Functions and Applications of Medicinal Plants,Guizhou Medical University,Guiyang 550014,China
  • Online:2024-05-28 Published:2024-05-29

Abstract:

To explore the anti-chronic myelogenous leukemia (CML) activity of rocaglamide (RocA) caused by aerobic glycolysis and potent molecular mechanism,the proliferation of CML cell line K562 inhibited by RocA were determined.The MTT assay showed that RocA inhibited the proliferation of K562 in a time-and dose-dependent way.The IC50 of K562 treated with RocA for 3 days was 21.70±5.68 nmol/L.Flow cytometry analyzed that the proportion of cells of G2/M phase was significantly increased.The apoptotic cells was significantly increased.RocA decreased the glucose consumption,lactate acid production and the protein expression of hexokinase 2 (HK2),c-Myc,which take an important part in aerobic glycolysis.The propagation rate,lactate acid production and the c-Myc protein expressionof K562 cells cultured without glucose was significantly lower than that cultured with glucose.After treatment with RocA,the inhibition on K562 cells cultured without glucose was significantly decreased compared to K562 cells cultured with glucose.Taken together,we presumed that RocA inhibited the proliferation of CML cells via apoptosis induction and cycle arrest partly through c-Myc/HK2 mediated aerobic glycolysis suppression.

Key words: rocaglamide, chronic myelogenous leukemia, aerobic glycolysis, c-Myc, HK2

CLC Number: